What type of study is this?

This is a Human Clinical Trial study.

What question did this study set out to answer?

This study aims to evaluate the safety and efficacy of a multi-drug regimen for patients with PCNS-DLBCL.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Clinical trial shows enhanced progression-free survival in PCNS-DLBCL with novel drug combinations, indicating improved safety outcomes.

This study aims to evaluate the safety and efficacy of a multi-drug regimen for patients with PCNS-DLBCL.
Conducted a phase 2 clinical trial with newly diagnosed PCNS-DLBCL patients.
Enrolled participants aged 18-90 from five centers in China.
Assessed clinical information, response rates, survival, and adverse events.
Achieved an overall response rate of 97.1% after two cycles of chemotherapy.
Documented progression-free survival rates of 86.8% at the 18-month mark.
Identified the TP53 gene and β2 microglobulin as key biomarkers in patient assessment.

Guoqiang Liu (2025) studied this question.

View Full Paper

Ask AI

Bookmark